En
Da
Fr
De
Sv
Deal History
About us
The Company
Team
Offices
Globalscope
Newsletter
Services
Corporate Finance
Debt Advisory
Equity Research
Growth Equity Financing
IPO Strategy & Preparation
Industries
Business Services
Consumer & Internet
Industrial Technology
Life Science
Software & TMT
Energy & Infrastructure
Research
Equity Research
Macro and Markets
Career
Events
Insights
News
Company News
Deal News
In the Media
Newsletter
Contact
Newsletter
En
Da
Fr
De
Sv
Main menu button
Worldwide
Worldwide
Canada
Denmark
France
Germany
Poland
Sweden
United Kingdom
USA
Team
Deals
Contact
Worldwide
Worldwide
Canada
Denmark
France
Germany
Poland
Sweden
United Kingdom
USA
Team
Deals
Contact
News
All
Abera Bioscience
Adventure Box
Adverty
All for One Group
ALM Equity
Alzecure Pharma
Arctic Minerals
Biosergen
Candles Scandinavia
Carlsquare
CDON
CellaVision
CSAM Health Group
DanCann Pharma
Ecoclime
Elicera Therapeutics
Enrad
Frequentis
FRISQ
Future Gaming
GHP Specialty Care
GIAB
H&D Wireless
Hanza
Herantis Pharma
InCoax
Kancera
Medclair Invest
Midsummer
Mindark PE
Modus Therapeutics
Moninvent
NeoDynamics
Nischer Properties
Nosa Plugs
Observit
Orion Corporation
Pharmiva
Raytelligence
Risk Intelligence
SBB i Norden
Sensec
Spotlight Group
Svenska Aerogel
Teneo AI
Thinc Jetty
Viva Wine Group
Ytrade Group
Zazz Energy
Zinzino
All
Company News
Deal News
Equity Research
Events
In the Media
Insights
Macro and Markets
07 Nov 2022
Research Update DanCann Pharma, Q3 2022: New agreement boosts prospects
Equity Research
DanCann Pharma
08 Jun 2022
Research Update DanCann Pharma, Q1 2022: Building pipeline ahead of launch
Equity Research
DanCann Pharma
15 May 2022
Mrkt BUZZ DanCann Pharma: Strengthens future pipeline by at least SEK 37 million
Equity Research
DanCann Pharma
24 Mar 2022
Research update DanCann Pharma Q4 2021: The start of a new era?
Equity Research
DanCann Pharma